The directive, titled Strengthening Customs Enforcement, mandates that the Department of Homeland Security restrict the use of informal customs entries for foreign importers. Starting October 22, secondary rules from Customs and Border Protection will further complicate international mail entry for goods subject to FDA oversight. While the order does not explicitly ban personal prescription imports, industry analysts anticipate that increased scrutiny will create significant delays for patients relying on international pharmacies.

SHARx executives argue that the burden of navigating these procedural hurdles falls heavily on employers who lack dedicated logistics support. To mitigate risk, the firm has spent the summer testing alternative entry processes and developing domestic sourcing options. CEO Corey Durbin stated that the company is prepared to shield clients from what he describes as a bureaucratic roller coaster, ensuring that cost-saving measures remain operational despite the regulatory shift. Chief Growth Officer Paul Pruitt noted that relying on a single import pathway leaves organizations vulnerable, emphasizing that long-term affordability requires redundant, dependable supply chains.